Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > REGULATORY
REGULATORY
- 68.3% of Public Comments Supported Mefeego Approval: MHLW
May 16, 2023
- G7 Health Chiefs Vow to Spur Antibiotic and Dementia Drug Development, Access to Vaccines
May 15, 2023
- Gene Therapy Luxturna Up for MHLW Panel Review on May 26
May 15, 2023
- Komeito Lawmakers Propose Review of Off-Year Re-Pricing, Correction of Multi-Product Small-Lot Generic Production
May 12, 2023
- MOF Continues to See Macroeconomic Indexing Reasonable: Panel Meeting
May 12, 2023
- LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
- Nonpartisan Lawmaker League OKs Dementia Bill, Eyes Enactment in Current Diet
May 11, 2023
- No Additional Safety Measures Needed at this Time for Xocova: Panel
May 11, 2023
- Label Revisions Ordered for 32 Hypertension Meds to Caution against Fetal Risks
May 10, 2023
- LDP’s Life Science League Submits Proposal; Ex-Minister Urges Price Debate from Industrial Policy Perspective
May 10, 2023
- MHLW Panel OKs 197 More Health Damage Claims for COVID Vaccines
May 10, 2023
- Chuikyo to Go Back Offline from May, but Online Viewing Still Available
May 9, 2023
- FY2023 COVID Booster Program Begins for Elderly, Health Workers
May 9, 2023
- Japan Shoots for 80% Replacement Rate in 60% of All Biosimilar APIs by FY2029
May 8, 2023
- PMDA, NHO Ink Database Deal, Data on 9 Million-Plus People to Be Available
May 8, 2023
- MHLW to Decide on Policy for Real-Time Supply Info System within FY2023: Official
May 8, 2023
- Japan Ends Priority Review for COVID Products with Severity Downgrade
May 8, 2023
- Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
- Japan Approves Mefeego as First Abortion Pill
May 1, 2023
- LDP League Calls for Generic Market Entry Rules to Ensure Supply: Draft Proposal
April 28, 2023
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…